Liraglutide as an effective tool for obesity management in type 1 diabetes – case report

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1-RA) are recommended for the management of type 2 diabetes as well as for obesity treatment. They have multiple effects, including stimulation of insulin secretion, inhibition of glucagon release, gastric emptying delay, and food intake suppression. Type I diabetes melitius (DMT1) requires life-long insulin therapy. However, obesity is caused by overeating; thus, additional insulin injections pose a risk for cardiovascular events, osteoarthritis, and obstructive sleep apnea. In this case report, we inform about a patient with DT1 and binge-eating behavior who used liraglutide 3.0 mg for 3 months for obesity management with significant improvement in HbA1c level (7.5% vs. 6.9%), weight (82.6 vs. 75.2 kg), BMI (32.3 vs. 29.4 kg/m2), waist circumference (94 vs. 88 cm), and leptin level (24.5 vs. 10.3 ng/ml). Further studies of GLP-1-RA in DT1 management can help to reduce the risks of obesity-related conditions and decrease the daily insulin dose requirement.